Atlanta-based pharmaceutical company Inhibikase Therapeutics Inc. (Nasdaq: IKT) has raised $10 million for development of treatments for Parkinson’s Disease and chronic myelogenous leukemia.
The investment included a $4.2 million in a private investment in public equity (PIPE) deal from New York-based Armistice Capital and $5.2 million from a confidentially marketed registered direct offering, said president and CEO Milton Werner. The remaining funds came from banking fees and commissions.
Funds…
